Literature DB >> 9345667

The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization.

J Hallas1, D Gaist, L Bjerrum.   

Abstract

The emergence of large, computerized pharmacoepidemiologic databases has enabled us to study drug utilization with the individual user as the statistical unit. A recurrent problem in such analyses, however, is the overwhelming volume and complexity of data. We here describe a graphical approach that effectively conveys some essential utilization parameters for a drug. The waiting time distribution for a group of drug users is a charting of their first prescription presentations within a specified time window. For a drug used for chronic treatment, most current users will be captured at the beginning of the window. After a few months, the graph will be dominated by new, incident users. As examples, we present waiting time distributions for insulin, ulcer drugs, systemic corticosteroids, antidepressants, and disulfiram. Appropriately analyzed and interpreted, the waiting time distributions can provide information about the period prevalence, point prevalence, incidence, duration of use, seasonality, and rate of prescription renewal or relapse for specific drugs. Each of these parameters has a visual correlate. The waiting time distributions may be an informative supplement to conventional drug utilization statistics, and possibly also a useful screening tool for unusual prescribing patterns.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9345667     DOI: 10.1097/00001648-199710000-00009

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  30 in total

1.  Impact of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care.

Authors:  M L Andersson; Y Böttiger; J D Lindh; B Wettermark; B Eiermann
Journal:  Eur J Clin Pharmacol       Date:  2012-07-01       Impact factor: 2.953

2.  Do immigrants from Turkey, Pakistan and Ex-Yugoslavia with newly diagnosed type 2 diabetes initiate recommended statin therapy to the same extent as Danish-born residents? A nationwide register study.

Authors:  Diana C Sanchez-Ramirez; Allan Krasnik; Helle Wallach Kildemoes
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

3.  Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model.

Authors:  Helle Wallach Kildemoes; Henrik Støvring; Morten Andersen
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

4.  Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.

Authors:  Lars J Kjerpeseth; Hanne Ellekjær; Randi Selmer; Inger Ariansen; Kari Furu; Eva Skovlund
Journal:  Eur J Clin Pharmacol       Date:  2017-07-22       Impact factor: 2.953

Review 5.  Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.

Authors:  Edward Chia-Cheng Lai; Nicole Pratt; Cheng-Yang Hsieh; Swu-Jane Lin; Anton Pottegård; Elizabeth E Roughead; Yea-Huei Kao Yang; Jesper Hallas
Journal:  Eur J Epidemiol       Date:  2017-07-11       Impact factor: 8.082

6.  The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.

Authors:  Anton Pottegård; Bine Kjøller Bjerregaard; Dorte Glintborg; Lisbeth Sandal Kortegaard; Jesper Hallas; Søren Ilsøe Moreno
Journal:  Eur J Clin Pharmacol       Date:  2012-07-19       Impact factor: 2.953

7.  Computing disease incidence, prevalence and comorbidity from electronic medical records.

Authors:  Steven C Bagley; Russ B Altman
Journal:  J Biomed Inform       Date:  2016-08-04       Impact factor: 6.317

8.  Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study.

Authors:  Anton Pottegård; Peter M Meegaard; Line H V Holck; Rene dePont Christensen; Hanne Madsen; Jesper Hallas
Journal:  Eur J Clin Pharmacol       Date:  2012-07-31       Impact factor: 2.953

9.  Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study.

Authors:  Anton Pottegård; Søren Friis; Morten Andersen; Jesper Hallas
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

10.  Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.

Authors:  Mitsutaka Takada; Mai Fujimoto; Kohei Yamazaki; Masashi Takamoto; Kouichi Hosomi
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.